You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023260019
Dec 20238407
Jan 202457010
Feb 20246606
Mar 20244002
Apr 20242207
May 20244003
Jun 20241002
Jul 20241802
Aug 2024801
Sep 20242802
Oct 20242203
Nov 20242602
Dec 20241204
Jan 20251205
Feb 2025502
Mar 2025001
May 2025003
Jun 2025005
Total710086